ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Negative Breast Carcinoma Expressing CEA
Interventions: DRUG: TF2 - 68 Ga-IMP-288:
Sponsor: Nantes University Hospital
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France|Gilead Sciences